Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) reported updated clinical results from the third dosing cohort of its Phase 1 trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE